INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC. (Nasdaq: BIOT) announced on September 30, 2026, that CelSiege Biosciences Inc. has appointed it as a non-exclusive authorized introduction and business development representative for IN01, a clinical-stage cancer immunotherapy, in Japan and the People's Republic of China. The appointment, formalized through a Letter of Authorisation signed on September 18, 2026, by CelSiege Founder and Director Johan Indot, allows BIOT to introduce the IN01 Program to potential strategic partners, investors, pharmaceutical and biotechnology companies, medical institutions, research organizations, and investment funds in both countries. BIOT may also facilitate preliminary discussions on potential investment, licensing, co-development, clinical development, manufacturing, and commercialization, though any definitive transaction remains subject to separate negotiations, due diligence, and definitive agreements.
The significance of this arrangement lies in its potential to accelerate the development and commercialization of a promising immunotherapy in two of the world's most critical oncology markets. Japan and China together host the largest lung cancer patient populations globally, and both possess world-class clinical research capabilities. As Tomoki Nagano, Chief Executive Officer of BIOT, stated, "We believe IN01 is a promising clinical-stage program in the field of active cancer immunotherapy, and we are fully committed to helping build a path for this science to reach the patients who need it." He added that the two countries are at the center of unmet medical needs in oncology and that BIOT shares with CelSiege a mission to bring the technology to patients. This appointment extends BIOT's business development activities into clinical-stage oncology, diversifying its portfolio beyond beauty, wellness, and regenerative medicine.
IN01 is an active immunotherapy, or therapeutic cancer vaccine, targeting epidermal growth factor (EGF). It is designed to stimulate the patient's immune system to produce antibodies against circulating EGF, a growth factor involved in the proliferation of certain cancer cells. Development materials identify squamous non-small cell lung cancer (sqNSCLC) as the lead indication, with potential expansion into colorectal, head-and-neck, and other cancers. IN01 is a clinical-stage asset and has not received marketing approval. The medical need is substantial: according to the International Agency for Research on Cancer, lung cancer was the world's most frequently diagnosed cancer in 2022, with approximately 2.5 million new cases and 1.8 million deaths. Non-small cell lung cancer accounts for approximately 80% to 85% of lung cancer cases, and Fortune Business Insights estimates the global NSCLC therapeutics market at approximately $38.49 billion in 2025. While this third-party estimate relates to a broad therapeutic category and should not be read as an estimate of IN01's addressable market or probability of success, it underscores the commercial interest in new treatments.
CelSiege Biosciences, headquartered in Marseille, France, with operations in the United States, focuses on active immunotherapies. Its proprietary B-cell-mediated platform is designed to stimulate polyclonal antibody responses against disease-associated ligands, with applications in oncology and other therapeutic areas. More information is available at CelSiege Biosciences. BIOT, a diversified healthcare and biotechnology company, seeks to build an integrated platform connecting innovative healthcare technologies with growth opportunities across Asia and other international markets. For more information, visit https://instinct-biot.com/.
This announcement matters because it signals BIOT's strategic move into clinical-stage oncology, leveraging its regional expertise to bridge a novel immunotherapy with partners in Japan and China. If successful, the collaboration could expedite the development of a new treatment option for lung cancer patients, addressing a significant unmet need. However, the non-exclusive nature of the appointment and the absence of definitive agreements mean that the path to commercialization remains uncertain. BIOT's ability to identify suitable partners and navigate regulatory landscapes in both countries will be critical. The news was initially distributed via NEWMEDIAWIRE.
